ArticleJAMA internal medicine2021
Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia.
Article in JAMA internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy of pharmacological interventions in COVID-19: A network meta-analysis.British journal of clinical pharmacology · 2022Pooled it
- Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.Annals of the rheumatic diseases · 2021Pooled it
- COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.Clinical pharmacology and therapeutics · 2021Trial
- Tocilizumab and IVIG experience during the service follow-up in patients with severe COVID-19 pneumonia.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Immunosuppressive dead cell as lung-targeting vehicle and cytokine absorption material for cytokine storm attenuation of pneumonia.Materials today. Bio · 2023Article
- COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.BioMed research international · 2023Review
- Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic.Osong public health and research perspectives · 2022Article
- Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19.Frontiers in immunology · 2022Article
- Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study.Journal of clinical medicine · 2021Article
- Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP).Infectious diseases and therapy · 2021Article
- Prevalence, prognostic value, pathophysiology, and management of hyponatraemia in children and adolescents with COVID-19.Acta bio-medica : Atenei Parmensis · 2021Review
- Treatment for COVID-19-a cohort study from Northern Italy.Scientific reports · 2021Observational
- Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry.European journal of medical research · 2021Observational
- Variation in therapeutic strategies for the management of severe COVID-19 in India: A nationwide cross-sectional survey.International journal of clinical practice · 2021Article
- MANAGEMENT OF ENDOCRINE DISEASE: Dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management.European journal of endocrinology · 2021Review
- Experience with the use of siltuximab in patients with SARS-CoV-2 infection.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021Article
- Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study.Journal of clinical pharmacy and therapeutics · 2021Article
- Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes.Journal of infection and public health · 2021Article
- What we learned in the past year in managing our COVID-19 patients in intensive care units?World journal of critical care medicine · 2021Review
- Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis.Journal of personalized medicine · 2021Article
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33079980What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.